<?xml version="1.0" encoding="UTF-8"?>
<p id="P16">A DLT was defined as any of the following treatment-emergent adverse events (TEAEs), considered by the investigator to be related to CC-486: a clinically significant grade ≥3 nonhematologic toxicity, including nausea, diarrhea, or vomiting despite adequate medical intervention; absolute neutrophil counts &lt; .5×10
 <sup>9</sup>/L lasting &gt;1 week despite myeloid growth factor support; platelets &lt; 10× 10
 <sup>9</sup>/L lasting &gt; 1 week despite transfusion support; failure to reach absolute neutrophil counts ≥ 1.0×10
 <sup>9</sup>/L and/or platelets ≥ 25×10
 <sup>9</sup>/L in the presence of a hypocellular bone marrow (&lt; 10%) within 56 days after the start of a treatment cycle; inability to initiate a subsequent cycle of CC-486 within 28 days of the anticipated start because of any treatment-related, non-hematologic TEAEs; and any toxic effect requiring dose reduction or treatment interruption.
</p>
